Subtopic Deep Dive
Antibiotic Susceptibility of Tropheryma whipplei
Research Guide
What is Antibiotic Susceptibility of Tropheryma whipplei?
Antibiotic susceptibility of Tropheryma whipplei refers to the in vitro and empirical testing of antimicrobial agents against this Whipple's disease causative bacterium, guiding clinical treatment regimens.
Key studies include Boulos et al. (2004) testing susceptibility in MRC5 cells (137 citations). Schneider et al. (2008) review pathogenesis and treatment aspects (361 citations). Lagier et al. (2010) highlight cultivation enabling susceptibility studies (250 citations).
Why It Matters
Determining T. whipplei susceptibility optimizes therapy for Whipple's disease, reducing relapse rates from empirical treatments. Boulos et al. (2004) identified effective agents like ceftriaxone and meropenem in cell culture. Schneider et al. (2008) and Marth and Raoult (2003) emphasize long-term regimens to prevent CNS involvement, as noted by Compain et al. (2013). Accurate profiles address cultivation challenges, improving outcomes in this rare infection.
Key Research Challenges
Difficult Cultivation
T. whipplei resists standard culture, limiting direct susceptibility testing. Lagier et al. (2010) achieved culture in 2000, enabling studies. Cell-based assays like MRC5 remain necessary (Boulos et al., 2004).
Empirical Treatment Reliance
Regimens derive empirically without MIC data for many antibiotics. Schneider et al. (2008) note variable responses necessitate prolonged therapy. Relapses occur despite treatment (Compain et al., 2013).
Resistance Profile Gaps
Limited data on emerging resistance due to rarity. Boulos et al. (2004) tested 18 antibiotics but gaps persist for newer agents. Genomic insights from Raoult et al. (2003) suggest potential mechanisms.
Essential Papers
Whipple's disease: new aspects of pathogenesis and treatment
Thomas Schneider, Verena Moos, Christoph Loddenkemper et al. · 2008 · The Lancet Infectious Diseases · 361 citations
Whipple's disease
Thomas Marth, Didier Raoult · 2003 · The Lancet · 278 citations
Systemic Tropheryma whipplei
Jean‐Christophe Lagier, Hubert Lépidi, Didier Raoult et al. · 2010 · Medicine · 250 citations
Culture of Tropheryma whipplei, the agent of Whipple disease (WD), was achieved in our laboratory in 2000, allowing new perspectives for the diagnosis of this disease and for the description of oth...
<i>Tropheryma whipplei</i> Twist: A Human Pathogenic Actinobacteria With a Reduced Genome
Didier Raoult, Hiroyuki Ogata, Stéphane Audic et al. · 2003 · Genome Research · 180 citations
The human pathogen Tropheryma whipplei is the only known reduced genome species (<1 Mb) within the Actinobacteria [high G+C Gram-positive bacteria]. We present the sequence of the 927,303-bp cir...
S2k-Leitlinie Gastrointestinale Infektionen und Morbus Whipple
Autoren:, Weitere Mitglieder der Leitlinienkommission in alphabetischer Reihenfolge einschließlich Affiliation: · 2015 · Zeitschrift für Gastroenterologie · 138 citations
Akute gastrointestinale Infektionen werden durch eine tbVielzahl bakterieller, viraler und parasitärer Erreger hervorgerufen. Der Krankheitsverlauf wird durch die Virulenz des jeweiligen Erregers, ...
Antibiotic Susceptibility of <i>Tropheryma whipplei</i> in MRC5 Cells
Areen Boulos, Jean‐Marc Rolain, Didier Raoult · 2004 · Antimicrobial Agents and Chemotherapy · 137 citations
ABSTRACT Whipple's disease is considered a rare chronic disease with a broad spectrum of clinical manifestations. Several antibiotics have been used for the treatment of this disease, and the curre...
Diagnosis of Whipple Disease by Immunohistochemical Analysis
Blaire L. Baisden, Hubert Lépidi, Didier Raoult et al. · 2002 · American Journal of Clinical Pathology · 112 citations
Whipple disease is a rare infection characterized clinically by diarrhea, fever, weight loss, arthralgia, malabsorption, and other systemic manifestations. The etiologic agent, Tropheryma whipplei,...
Reading Guide
Foundational Papers
Start with Boulos et al. (2004) for direct susceptibility data in MRC5 cells; Schneider et al. (2008) for treatment context; Lagier et al. (2010) for cultivation enabling tests.
Recent Advances
Raoult et al. (2003) genome provides resistance gene insights; Compain et al. (2013) addresses CNS relapse treatment failures.
Core Methods
MRC5 cell culture for MIC determination (Boulos et al., 2004); axenic cultivation (Lagier et al., 2010); empirical regimens validated by clinical outcomes (Schneider et al., 2008).
How PapersFlow Helps You Research Antibiotic Susceptibility of Tropheryma whipplei
Discover & Search
Research Agent uses searchPapers('Tropheryma whipplei antibiotic susceptibility MRC5') to find Boulos et al. (2004), then citationGraph to map 137 citing works, and findSimilarPapers for Lagier et al. (2010) cultivation advances.
Analyze & Verify
Analysis Agent applies readPaperContent on Boulos et al. (2004) to extract MIC values, verifyResponse with CoVe against Schneider et al. (2008), and runPythonAnalysis to plot susceptibility data via pandas for statistical verification. GRADE grading assesses evidence quality for treatment recommendations.
Synthesize & Write
Synthesis Agent detects gaps in resistance data across Boulos et al. (2004) and Raoult et al. (2003), flags contradictions in empirical vs. in vitro results. Writing Agent uses latexEditText for regimen tables, latexSyncCitations, latexCompile, and exportMermaid for treatment flowchart diagrams.
Use Cases
"Plot MIC values for T. whipplei antibiotics from Boulos 2004"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib plot) → researcher gets MIC bar chart with stats.
"Draft LaTeX review of T. whipplei susceptibility studies"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Boulos 2004, Schneider 2008) + latexCompile → researcher gets compiled PDF with figures.
"Find code analyzing Whipple's antibiotic data"
Research Agent → paperExtractUrls (Raoult 2003 genome) → paperFindGithubRepo → githubRepoInspect → researcher gets repo with Actinobacteria susceptibility scripts.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'Tropheryma whipplei susceptibility', chains citationGraph → readPaperContent → GRADE, outputs structured review with susceptibility table. DeepScan applies 7-step CoVe to verify Boulos et al. (2004) MICs against Lagier et al. (2010). Theorizer generates hypotheses on resistance from Raoult et al. (2003) genome and treatment data.
Frequently Asked Questions
What is antibiotic susceptibility of Tropheryma whipplei?
It evaluates antimicrobial efficacy against T. whipplei, tested in MRC5 cells by Boulos et al. (2004) showing activity for ceftriaxone, rifampin, and meropenem.
What methods test T. whipplei susceptibility?
Cell culture in MRC5 cells determines MICs (Boulos et al., 2004). Cultivation advances by Lagier et al. (2010) support axenic growth for testing.
What are key papers on this topic?
Boulos et al. (2004, 137 citations) details MRC5 susceptibility; Schneider et al. (2008, 361 citations) covers treatment; Lagier et al. (2010, 250 citations) enables culture-based studies.
What open problems exist?
Gaps in MIC data for newer antibiotics and clinical resistance monitoring persist due to rarity. Relapse mechanisms need genomic correlation (Raoult et al., 2003).
Research Whipple's Disease and Interleukins with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antibiotic Susceptibility of Tropheryma whipplei with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers